This is one
kind of the acute leukaemias. When we find out that we have some kind of disease the, the first thing that comes in to our mind is “is it curable?’ So the leukaemic patients also think the same way. For diseases such as cough and cold, the answer is very straight forward and easy, but leukaemia is not such simple disease, so we cannot give a simple straight forward answer.
Leukaemia is a complex disease and as a result of that complexity, there is a wide variety of presentation of the disease. Not only that, the response to treatment also differs from patient to patient.
According to the previous data, acute myeloid leukaemia can be curable in some patients. The next question is ‘who are the people that can be cured?” Well “yes” but for some. Generally adults who are under 60 years old are treated with curative intent, but not all. Those who have other co morbidities (other significant illnesses) are not treated with curative intent.
Out of those who are treated, some may fail to eliminate the disease entirely. The physician categorizes the disease as low risk and high risk. This is done according to the cytological (the cellular) pattern. So if you belong to the
low risk group, you will be treated with “Moderately intensive combination chemotherapy”. This always includes an anthracycline. Examples of anthracycline include daunorubicin and cytosine arabinose. Then at least 4 cycles of treatment will be given for
consolidation. These treatments are given at 3-4 week intervals.
Things are a little harder for patients who are grouped as ‘high risk’. This category of patients is treated with curative intent only if they have an HLA-identified sibling. What is meant by “HLA-identified sibling”? HLA can be simplified as a marker of the tissues. Different people differ in their HLA type. If two persons are HLA compatible, it means that their tissues are also more or less identical to each other. So, tissues can be transplanted between such people without getting rejected. Why do they need a HLA-identified sibling?
It is because the treatment may need stem cell transplantation and these stem cells can only be taken from a HLA-identified sibling for it not to be rejected.
Most of the people with acute myeloid belongs to the elderly age group, but it is a very sad situation because those patients cannot be treated with curative intent, because the treatment it self carries a very high morbidity rate for elderly patients. The toxicity of the treatment is very high so that they cannot bear that much of toxicity.
There is another group of patients who are at intermediate risk. In these patients remission is induced by giving consolidating chemotherapy. Thereafter they will be treated with sibling matched allogenic transplantation.
With all above mentioned interventions, 75% of the patients who are under 60 years of age may achieve complete remissions. If a patient fails to achieve complete remission it could be due to one of the following causes.
1. Resistant leukaemia
2. Infection – the disease and the treatment both make the patient Immunocompromised. Therefore, they are more prone to get infections and these infections can be severe enough to cause death.
3. Bleeding – The patients may become severely thrombocytopenic and that could lead to fatal haemorrhage. This is a rare cause of failure of treatment.
Only half of the patients who successfully achieve complete remission will get completely cured. Recurrence of the disease is sign of bed prognosis because it is very hard to achieve a longer life time when the disease recurs. The prognosis found to be bad even the physicians are able to achieve a second remission. The only thing that improves the survival rate is allogenic transplantation.
Still the patients with acute myeloid leukaemia should not give up their hopes because there are a lot of experimental therapies going on at the time.
References : Kumar P and Clark M, 2009. Clinical Medicine. 7th ed.